SGHT · Sight Sciences, Inc.
$8.26
+0.11 (+1.35%)
At close · Aug 21
Market Cap
$455.03M
Shares
55.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.26
Open$8.25
Day$8.05–8.35
52W close$3.20–9.05
Avg vol 30d264K
Short int827K · 1.5% float · 5.5d
Short vol32%
Last earningsAug 5, 2026
DataJul 2021–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
Golden cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
+40%
above
RSI (14)
75
overbought
MACD trend
Positive
52-week position
86%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+68%
trailing
6-month return
+47%
trailing
YTD return
+4%
this year
Relative strength
+35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Golden cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$68.8K over 90 days · 0% sells
Short interest
Falling
1.50% of float · ▼ -0.4% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
111 holders — near 3-yr high, broad support
Squeeze score
66
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
86%
expanding
EPS growth
+28%
Y/Y
Free cash flow
$-29.9M
Balance sheet
$51.7M
net cash
Quant / Vol
risk profile
Volatility
84%
annualized · 1-yr
Max drawdown
−62%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Interventional Glaucoma revenue
· full year 2026
Initiated
$79M – $81M
Prior guidance
period ended
· from the 8-K filed Jan 13, 2026
Total revenue
· fourth quarter 2025
$20.3M – $20.4M
Surgical Glaucoma revenues
· fourth quarter 2025
$19.6M – $19.7M
Total revenue
· full year 2025
$77.3M – $77.4M
Dry Eye revenues
· fourth quarter 2025
$700,000
Surgical Glaucoma revenues
· full year 2025
$75.6M – $75.7M
Dry Eye revenues
· full year 2025
$1.6M
Guided vs delivered
· last 3 settled
Revenue
full year 2025
guided $76M – $78M
$77.36M
In line
Revenue
full year 2024
guided $81M – $85M
$79.87M
Miss −3.8%
Annual revenue guidance
annual
guided $89M – $94M
$81.06M
Miss −11.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
Golden cross
Bullish
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
+40%
Bullish
RSI (14)
75
Bearish
MACD trend
Positive
Bullish
52-week position
86%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 4 of 6
Trend (MA cross)
Golden cross
50d $6 › 200d $6 — 50d above 200d
Institutional flow
Distributing
-3% holders QoQ · +16 funds added
Insider flow
Accumulating
Net +$68.8K over 90 days · 0% sells
Short interest
Falling
1.50% of float · ▼ -0.4% MoM · 5.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
111 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $8 · 86%
Range high $9
vs 200-day avg +44%
vs 50-day avg +40%
50-day above 200-day golden cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Operating Expenses non-GAAP | 43.49M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Dry Eye active customers | 176 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Dry Eye lid treatment units sold | 3,091 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Glaucoma active customers | 1,214 | Three Months Ended June 30, 2026 | — |
|
|
|||
| Interventional Glaucoma gross margin | 89.9% | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SGHT
this stock
Sight Sciences, Inc.
|
$455.03M | +4.2% | -3.1% | — | 1.5% |
|
ABT
Abbott Laboratories
|
$203.17B | -6.9% | +5.7% | 32.7 | 1.3% |
|
SYK
Stryker Corp
|
$126.37B | -6.3% | +11.2% | 34.1 | 2.2% |
|
MDT
Medtronic plc
|
$119.49B | -2.8% | +8.4% | 25.0 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.00B | -47.2% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SGHT | +1.5% | +68.2% | +47.0% | +57.0% | +4.2% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +2.8% | +64.6% | +35.4% | +54.5% | -8.1% |
Key facts
CIK
1531177
CUSIP
82657M105
13F (30d)
101 filings
101 filers
Visit website
Investor relations